STAROPOLI, Nicoletta
 Distribuzione geografica
Continente #
NA - Nord America 313
EU - Europa 306
AS - Asia 184
SA - Sud America 14
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 821
Nazione #
US - Stati Uniti d'America 297
IT - Italia 166
SG - Singapore 137
DE - Germania 57
CN - Cina 19
FI - Finlandia 19
GB - Regno Unito 19
CA - Canada 15
BR - Brasile 13
SE - Svezia 12
RU - Federazione Russa 11
HK - Hong Kong 8
NL - Olanda 7
IN - India 6
TR - Turchia 5
CZ - Repubblica Ceca 4
AT - Austria 3
FR - Francia 3
BD - Bangladesh 2
JP - Giappone 2
PK - Pakistan 2
PL - Polonia 2
VN - Vietnam 2
ZA - Sudafrica 2
AU - Australia 1
CL - Cile 1
ES - Italia 1
EU - Europa 1
ID - Indonesia 1
PT - Portogallo 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
Totale 821
Città #
Singapore 81
Munich 46
Chandler 44
Chicago 22
Santa Clara 21
Turku 18
London 17
Milan 17
Ashburn 15
Carbonia 12
Catanzaro 12
Naples 11
Rome 11
Lawrence 10
Princeton 10
Hong Kong 8
The Dalles 8
Wilmington 8
Los Angeles 7
Ottawa 7
Parma 7
Boardman 5
Beijing 4
Ercolano 4
Melito di Porto Salvo 4
Montreal 4
Olomouc 4
Reggio Calabria 4
Afragola 3
Moscow 3
Nuremberg 3
Redmond 3
Santo Stefano di Rogliano 3
Amsterdam 2
Ankara 2
Benevento 2
Bisignano 2
Catania 2
Cavallino 2
Charlotte 2
Dallas 2
Des Moines 2
Esslingen am Neckar 2
Gatchina 2
Hanoi 2
Jiaxing 2
Lahore 2
Marcianise 2
Mountain View 2
Phoenix 2
Romainville 2
San Nicola Manfredi 2
Seattle 2
Serra San Bruno 2
Shenzhen 2
Spezzano della Sila 2
St Petersburg 2
Stockholm 2
Tokyo 2
Warsaw 2
Washington 2
West Lafayette 2
Acri 1
Alvorada 1
Atlanta 1
Augusta 1
Bengaluru 1
Berlin 1
Bismarck 1
Bologna 1
Boston 1
Brooklyn 1
Buffalo 1
Campinas 1
Canberra 1
Cape Town 1
Chaguanas 1
Chelyabinsk 1
Chennai 1
Clearwater 1
Columbus 1
Corona 1
Cosenza 1
Crestview 1
Flint 1
Ginosa 1
Guangzhou 1
Gunzenhausen 1
Helsinki 1
Houston 1
Irving 1
Istanbul 1
Itariri 1
Jaraguá do Sul 1
Johannesburg 1
Kensington 1
Kolkata 1
Landshut 1
Limeira 1
Lithonia 1
Totale 532
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 78
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 50
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 43
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 41
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 39
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 37
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 37
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 36
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 36
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 36
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 35
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 35
Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations 32
Ramucirumab In Gastric Cancer Treatment: An Economic Evaluation 31
Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections 31
Prevalence of Non-Erosive Esophageal Phenotypes in children: a European multicenter study 24
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 23
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity 21
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 19
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 17
First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis 15
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 14
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 14
LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation 14
Cardiotoxicity of anti-HER2 drugs in the treatment of metastatic breast cancer: Case report 13
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) 12
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 11
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis 8
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis 7
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program 7
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 6
Why Do You Treat pCR Patient With Pertuzumab and Trastuzumab? 6
Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper 2
Totale 874
Categoria #
all - tutte 9.393
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.393


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127 3 0 0 2 3 3 1 0 5 9 1 0
2021/202244 0 0 1 17 0 2 0 8 4 8 2 2
2022/2023171 22 9 5 8 14 13 4 7 25 28 31 5
2023/2024135 41 10 12 6 7 25 1 1 0 7 13 12
2024/2025487 31 13 8 7 20 77 15 19 42 8 104 143
2025/20261 1 0 0 0 0 0 0 0 0 0 0 0
Totale 874